NASDAQ Co. Focused on CRISPR Gene Editing Technology from the Broad Institute of MIT and Harvard: Aridis Pharmaceuticals, Inc. (Stock Symbol: ARDS) – MENAFN.COM

SourceMENAFN
SectorTechnology
CountryMiddle east

Proprietary Products Currently in Clinical Trials Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) discovers and develops anti-infectives to be used as first-line treatments to combat antimicrobial resistance (AMR) and viral pandemics. ARDS is utilizing its proprietary ʎPEX and MabIgX® technology platforms to rapidly identify rare, potent antibody-producing B-cells from patients who have successfully overcome an infection, and to rapidly manufacture monoclonal antibody (mAbs) for therapeutic treatment of critical infections.

These mAbs are already of human origin and functionally optimized by the natural human immune system for high potency. Hence, they are already fit-for-purpose and do not require further engineering optimization to achieve full functionality. ARDS has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antibacterial and antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to...read more...